When a drug first hits the market, lifecycle management (LCM) teams have a host of weapons in their arsenal to increase market share. As that same drug approaches patent expiry, the choices become more limited. But all hope is not lost! Here are three late-stage lifecycle management tactics highlighted in our new report with a track-record of success:
- Pediatric exclusivity
- Strategic pricing
- Medical publications
Ever since the FDA and EMA each released separate position papers, sponsors and CROs alike have been focused on implementing risk-based monitoring (RBM) strategies, rather than performing traditional monitoring for each of their clinical trials. And why not? A look at the costs and benefits of traditional site monitoring activities shows that these two metrics do not always align favorably. According to an article published in Perspectives in Clinical Research, clinical site monitoring accounts for “30% of total clinical trial cost.” However, the same article estimates that the source data verification (SDV) that CRAs conduct during these in-person site visits account for “less than 3% of data changes performed after CRA visits.” If there’s no discernible benefit for sponsors and CROs to visit sites more often, it follows that companies would look to reduce the number of in-person site visits they schedule by using risk-based monitoring strategies instead. Continue reading
As life sciences companies cultivate a more global reach, the medical information function must also grow to span worldwide operations. For many companies, this means maintaining a number of medical information groups — including both a global function and localized teams, in addition to a more established call center system. The ways in which these global, regional and country-level teams work together drive team activities and also determine pharmaceutical call center structure. Continue reading
One of the interesting trends over the past few years for those of us watching the pharmaceutical industry is how companies are turning increasingly to specialization within their portfolios. Pharmaceutical divestitures are continuing at breakneck pace as companies look to shed products that fall outside primary business interests and scour the market for products or pipelines that match up with development priorities. So why is this happening now and how will it further shape the industry? Continue reading
According to a Cutting Edge Information study, attaining favorable Medicaid pricing remains a key factor in life science companies’ market access preparations. Broadly, government payer acceptance often sets the precedent for whether private payers will reimburse company products or not. Unsurprisingly, private payers are less likely to support products that fail to meet government approval. As one market access advisor explained, “Failure to receive Medicaid coverage is like a kiss of death for company products.” Subsequently, market access teams work diligently to ensure that drugs attain Medicare and Medicaid reimbursement. Continue reading
If it looks like a medical device and it works like a medical device, it’s probably a medical device.
App developers, the wait is over! The FDA has finally released its guidance on mobile medical applications. The guidance describes the types of apps that are covered under FDA oversight and those left to the discretion of app developers. Continue reading
Pharmaceutical companies are evolving their advisory board strategies to keep pace with the rapid changes that the entire industry is experiencing. As payer demands increase in complexity, the importance of engaging payers to understand their needs is growing. The depth of outcomes data that payers need requires precisely targeted clinical trials to be effectively developed to meet these needs. As such, when a team is able to gather a roomful of experts together, the benefits from that time need to be maximized for both the participants’ and the company’s sake. One significant — and relatively simple — step that companies can take is to ensure that the moderator or co-chair is up to the task. Continue reading
Generations of hopeful party planners and anxious hostesses have turned to Emily Post as the authority on all things etiquette. Her gentle but firm guidelines on manners and social norms may seem more appropriate for old-fashioned ladies throwing summer soirees or bridal luncheons than they do for high-powered life science industry executives who are delving into the latest clinical research or marketing strategies. Although pharmaceutical companies specialize in developing innovative cures, looking back to the traditional truths of hosting etiquette lends value to advisory boards. Here is a look at successful pharmaceutical advisory board management through the lens of the Emily Post Institute’s Six Ways to Be a Good Host. Continue reading
Pesky mosquitoes have forced an early end to many swampy summer nights. But these parasites pose a much greater risk for the nearly 200 million people infected with malaria each year. In a small Phase 1 clinical trial, a potential vaccine demonstrated encouraging results. PfSPZ was highly effective in patients receiving the highest dose. Developed by biotechnology firm Sanaria, the vaccine is in early testing stages. Although the results are promising, they need to be replicated on a bigger scale and evaluated over time to determine how long the protection lasts. Continue reading
The key to weight loss is to burn more calories than you consume. Most weight-loss drugs facilitate this process by curbing their patients’ appetites as they diet and exercise. But what if there were a drug that increased caloric burn without making a patient eat less?
Zafgen Inc. may have developed this proverbial miracle drug. The injectable suspension, called Belonarib (ZGN-440), blocks methionine aminopeptidase 2 (MetAP2) — an enzyme that helps to produce fatty acids. As a result, Belonarib works to increase metabolic rates and decrease fat production. All without diet and exercise. Continue reading